Biomarker panel for chronic graft-versus-host disease

Jeffrey Yu, Barry E. Storer, Kushi Kushekhar, Mohammad Abu Zaid, Qing Zhang, Philip R. Gafken, Yuko Ogata, Paul J. Martin, Mary E. Flowers, John A. Hansen, Mukta Arora, Corey Cutler, Madan Jagasia, Joseph Pidala, Betty K. Hamilton, George L. Chen, Iskra Pusic, Stephanie J. Lee, Sophie Paczesny

Research output: Contribution to journalArticlepeer-review

87 Scopus citations


Purpose: To identify diagnostic and prognostic markers of chronic graft-versus-host disease (cGVHD), the major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Patients and Methods: Using a quantitative proteomics approach, we compared pooled plasma samples obtained at matched time points after HCT (median, 103 days) from 35 patients with cGVHD and 18 without cGVHD (data are available via ProteomeXchange with identifier PXD002762). Of 105 proteins showing at least a 1.25-fold difference in expression, 22 were selected on the basis of involvement in relevant pathways and enzyme-linked immunosorbent assay availability. Chemokine (C-X-C motif) ligand 9 (CXCL9) and suppression of tumorigenicity 2 (ST2) also were measured on the basis of previously determined associations with GVHD. Concentrations of the four lead biomarkers were measured at or after diagnosis in plasma from two independent verification cohorts (n = 391) to determine their association with cGVHD. Their prognostic ability when measured at approximately day +100 after HCT was evaluated in plasma of a second verification cohort (n = 172). Results: Of 24 proteins measured in the first verification cohort, nine proteins were associated with cGVHD, and only four (ST2, CXCL9, matrix metalloproteinase 3, and osteopontin) were necessary to compose a four-biomarker panel with an area under the receiver operating characteristic curve (AUC) of 0.89 and significant correlation with cGVHD diagnosis, cGVHD severity, and nonrelapse mortality. In a second verification cohort, this panel distinguished patients with cGVHD (AUC, 0.75), and finally, the panel measured at day +100 could predict cGVHD occurring within the next 3 months with an AUC of 0.67 and 0.79 without and with known clinical risk factors, respectively. Conclusion: We conclude that the biomarker panel measured at diagnosis or day +100 after HCT may allow patient stratification according to risk of cGVHD.

Original languageEnglish (US)
Pages (from-to)2583-2590
Number of pages8
JournalJournal of Clinical Oncology
Issue number22
StatePublished - Aug 1 2016

Bibliographical note

Funding Information:
Supported by the National Marrow Donor Program through the Amy Strelzer Manasevit Scholar Grant No. 200513 (S.P.) and National Institutes of Health (NIH) Grants No. R01CA174667 (S.P.), R01CA118953 (S.J.L.), and U54CA163438 (S.J.L.). The Chronic Graft-Versus-Host Disease Consortium (Grant No. U54 CA163438) is part of the National Center for Advancing Translational Science (NCATS) Rare Diseases Clinical Research Network (RDCRN). RDCRN is an initiative of the Office of Rare Disease Research, NCATS, funded through a collaboration between NCATS and the National Cancer Institute. The Fred Hutchinson Cancer Research Center Proteomics Facility is partially funded by Cancer Center Support Grant No. P30 CA015704 from the NIH.

Publisher Copyright:
© 2016 by American Society of Clinical Oncology.


Dive into the research topics of 'Biomarker panel for chronic graft-versus-host disease'. Together they form a unique fingerprint.

Cite this